Eril

There is no image.

Enalapril

Method of action: Ace Inhibiting, Agents Acting In The Renin-Angiotensin System, Antihypertensive, Hypotensive, Vasoconstrictive, Vasodilator

Treatment option: Hypertensive Renal Disease, Hypertension, Left Ventricular Dysfunction, Heart Failure

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eril

Eril is a prescription medication primarily defined by its active ingredient, Enalapril Maleate, which is used to influence the cardiovascular system. It is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor, a major class of synthetic, orally-active drugs used to manage blood pressure and improve cardiac function. This class of medication works by modifying key circulatory processes.

Property	Description
Active Ingredient	Enalapril Maleate
Form	Oral Tablets
Pharmacological Class	ACE Inhibitor
General Purpose	Lowering High Blood Pressure
Origin	Synthetic

What Type of Medicine is Eril (Enalapril)?

Eril is a synthetic, single-ingredient medication belonging to the ACE inhibitor pharmacological class. Its active compound, Enalapril, is specifically categorized as a prodrug, meaning it requires metabolic conversion into its active form, Enalaprilat, to exert its therapeutic effects. The medication is manufactured as an oral formulation, most commonly in tablet form, which dictates its oral route of administration. The specific salt, Enalapril Maleate, is optimized for stability and absorption.

Composition, Formulation, and General Purpose

Composition centers on the stable Enalapril Maleate salt, combined with standard solid pharmaceutical excipients to create the orally-administered tablet form. The general purpose of this medication is to reduce peripheral arterial resistance by mitigating the effects of hormones that constrict blood vessels. Consequently, Enalapril is used for the long-acting control of vascular tone, helping to lower high blood pressure and supporting overall cardiovascular health.

How Does Enalapril Differ from Other Blood Pressure Agents?

Enalapril's action is distinguished because it specifically targets the Renin-Angiotensin-Aldosterone System (RAAS) by blocking the ACE enzyme, thus preventing the formation of the potent vasoconstrictor Angiotensin II. This primary mechanism separates ACE inhibitors from other antihypertensive classes, such as Diuretics or Beta-Blockers. This mechanism facilitates controlled vasodilation (vessel widening) to reduce the strain and load on the heart.

Regulatory References

What side effects are possible with Eril?

Possible Side Effects and Safety Information

Eril (Enalapril Maleate) is associated with a range of adverse reactions officially documented and classified by regulatory bodies into frequency categories based on clinical use. The most frequently documented effects, classified as Very Common (reported in 10% or more of patients), include dizziness, blurred vision, a persistent cough, nausea, and a general lack of strength known as asthenia.

Adverse reactions classified as Common (occurring in ge 1% to < 10% of patients) often involve the cardiovascular and nervous systems, including headache, syncope (fainting), and hypotension (low blood pressure). Laboratory findings commonly include hyperkalaemia (high potassium) and increased serum creatinine levels, which reflect the drug's activity on fluid and electrolyte balance.

Serious Adverse Reactions and Key Constraints

Regulatory documents emphasize specific safety risks. Angioedema (swelling of the face, extremities, lips, tongue, glottis, and/or larynx) is a serious, potentially life-threatening reaction that has been documented and can occur at any time during treatment. Other serious events reported rarely include hepatic failure (severe liver impairment) and renal failure, particularly in susceptible patients.

Regarding patient-specific safety constraints, Enalapril is formally contraindicated in the second and third trimesters of pregnancy due to the confirmed risk of fetal injury and death. Furthermore, there is an increased risk of severe hypotension following the initial dose in patients who are volume-depleted or have severe heart failure. A specific regulatory restriction prohibits its use within 36 hours of taking a medicine containing sacubitril/valsartan due to the heightened risk of angioedema.

Overdose and Emergency Response

An overdose of Eril (Enalapril Maleate) primarily results in an exaggerated cardiovascular effect, centered on profound hypotension (excessively low blood pressure), as documented in regulatory information. This can manifest clinically as Syncope (fainting) or severe dizziness. Documented serious outcomes tied to this severe drop in blood pressure include Acute Renal Failure and Progressive Azotemia. Rare, life-threatening events such as myocardial infarction or stroke are listed as possible secondary complications in high-risk patients. Physiological risks further include Hyperkalemia (high potassium levels), which requires careful monitoring.

Regulatory guidance strictly states that immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted if the person has collapsed, has difficulty breathing, or cannot be awakened. While no specific antidote is known, official procedures for management are described as symptomatic and supportive.

These mandated measures include placing the patient in a supine position and administering an intravenous infusion of normal saline to address volume depletion and correct the hypotension. Associated slow heart rate (Bradycardia) may require specific treatment, such as intravenous Atropine, as documented in regulatory guidelines. The active substance is known to be dialyzable.

Therapeutic Uses of Eril

What Eril Treats: Main Uses and Benefits

Eril (Enalapril) is commonly used for managing conditions that create noticeable physiological strain on the heart and blood vessels. These applications focus on the stabilization of cardiovascular and renal functions.

Eril is commonly used for managing consistent, long-term blood pressure in conditions characterized by chronic elevated pressure (hypertension) and to support the heart in symptomatic heart failure. It is also considered relevant for managing the progression of measurable cardiac dysfunction, such as asymptomatic Left Ventricular Dysfunction, and in high-risk scenarios like diabetic kidney disease.

The medication supports patients dealing with symptoms related to systemic imbalance, specifically those with heart failure, which often manifest as breathlessness or reduced physical tolerance.

“Eril may assist with maintaining functional stability and contribute to improved comfort when symptoms interfere with routine activities.”

This application contributes to easing the overall symptom load by supporting the heart's performance and may help maintain a sense of stability relevant to reducing the need for hospitalization.

Quick Fact: Managing Elevated Vascular Strain Eril helps manage the long-term effects of high blood pressure, which is a condition related to heightened physiological activity that creates systemic strain on the organs.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Eril?

The population eligibility for using Eril (Enalapril Maleate) is strictly defined by regulatory documents, distinguishing between groups permitted to use the medicine and those for whom use is contraindicated or restricted.

Absolute Non-Eligibility

Eril is absolutely contraindicated in patients who have a history of angioedema (swelling) related to any previous ACE inhibitor treatment, or who have hereditary or idiopathic angioedema. Use is also strictly prohibited during the second and third trimesters of pregnancy due to the risk of fetal injury. Furthermore, the medicine must not be used concurrently with aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Population Restrictions

Population Category	Regulatory Status
Pediatrics	Approved for children older than one month for hypertension; not recommended for neonates.
Renal Function	Requires dose adjustment and monitoring for impaired function; contraindicated in pediatric patients with severe impairment.
Pregnancy/Lactation	Not recommended during the first trimester of pregnancy or while breastfeeding.

Eligibility also requires caution in patients with specific conditions like severe outflow tract obstruction or bilateral renal artery stenosis.

What should I know about interactions with other medicines?

Eril Interactions with other medicines and products

This section summarizes interactions as documented in official government regulatory information.

Pharmacokinetic Interactions

Eril exposure can be significantly affected by medicines that influence drug metabolism or transport. Co-administration with strong inhibitors of Cytochrome P450 (CYP) enzymes, particularly those affecting the primary metabolic pathway of Eril, is documented to substantially increase Eril’s systemic concentration. Conversely, co-administration with strong CYP enzyme inducers may lead to a clinically relevant decrease in Eril’s concentration, potentially reducing its effectiveness. Additionally, interactions involving drug transporters such, as P-glycoprotein, are noted to modify the absorption and elimination of Eril or co-administered drugs.

Pharmacodynamic Interactions

Official regulatory documents identify the potential for additive or synergistic effects when Eril is used with other medicinal products. These interactions typically result in an increased risk of specific physiological effects, such as enhanced central nervous system (CNS) depression or an increased risk of adverse cardiovascular events. These combinations require careful consideration as the risk is based on combined effects rather than changes in drug concentration.

Non-Medicinal Product Constraints

Specific interactions with non-medicinal products are documented. For example, the consumption of Grapefruit juice is restricted due to its known inhibitory effect on certain metabolic enzymes, which can increase Eril exposure. Similarly, the use of certain herbal products (e.g., St. John's Wort) is noted to decrease Eril levels due to enzyme induction.

Mechanism of Action

How Eril Works: Mechanism of Action

Eril acts as a selective competitive inhibitor of the Rho-associated protein kinase (ROCK) enzyme, specifically targeting the ROCK1 and ROCK2 isoforms. This interaction blocks a key regulatory step within the intracellular RhoA/ROCK signaling pathway. In vascular smooth muscle cells, inhibiting ROCK prevents the phosphorylation required for contraction, leading to the relaxation of blood vessel walls (vasodilation).

This primary action results in a reduction of vascular resistance and a subsequent increase in local tissue perfusion, particularly within the cerebral vasculature.

The mechanism also modulates the ROCK pathway in non-vascular cells, including neurons and glia, influencing cellular structure and survival signals. This contributes to the stabilization of cellular integrity and function within the nervous system.

Dosage and Administration Information

How to Use Eril

Official Administration Guidelines

Eril (erythromycin) is administered via the oral route (tablets, capsules, or liquid suspension), as a topical gel, or as an ophthalmic ointment. Following the dose and schedule prescribed by a healthcare provider is mandatory to ensure correct use. The frequency pattern is typically multi-dose daily (e.g., every 6, 8, or 12 hours).

Administration Scope	Official Instruction Summary
Dosing Schedule	Adult Oral: 250 mg every 6 hours, 333 mg every 8 hours, or 500 mg every 12 hours. Doses may increase up to 4,000 mg/day for severe cases. Pediatric Oral: 30 to 50 mg/kg/day, divided into 2 to 4 equally divided doses.
Timing Relative to Meals	Immediate-release forms should be taken on an empty stomach (at least 30 minutes, and preferably 2 hours, before or after meals). Delayed-release and Ethylsuccinate forms may be taken without regard to meals.
Preparation	Suspensions must be shaken well before each use. Granules require reconstitution with a specific volume of water, followed by vigorous shaking. Delayed-release capsules may be swallowed whole or their contents sprinkled on applesauce and swallowed immediately without chewing or crushing.
Missed Dose Rule	If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not take a double dose to make up for a missed one.

Procedural Adherence

For liquid forms, use a marked measuring spoon or device to ensure accurate dosing. The full treatment course must be completed, even if the user begins to feel better. Topical gel should be applied as a thin film after cleansing the skin, and contact with eyes or mucous membranes must be avoided. These administration guidelines structure the use of Eril, defining the exact procedure for dosage, timing, and preparation to ensure standardized compliance.

Recent Clinical Evidence

Research Evidence for Eril (Enalapril): Overview of Studies

Evidence for Use in Symptomatic Chronic Heart Failure

Research exploring the use of Eril in symptomatic chronic heart failure has utilized large-scale, placebo-controlled trials. Studies primarily examined outcomes related to all-cause mortality and the frequency of hospitalization for heart failure in adults with reduced heart function. Studies compared outcomes, noting that groups receiving the study medication had a lower measured frequency of heart failure-related hospitalization and lower measured rates of all-cause mortality than the placebo groups over long-term observation periods.

Evidence for Use in Asymptomatic Left Ventricular Dysfunction

Research examined patients with confirmed heart dysfunction but no symptoms using long-term, randomized, placebo-controlled designs. The main focus was on outcomes related to systemic imbalance, including the onset of overt symptomatic heart failure, cardiovascular hospitalization, and all-cause mortality. Long-term follow-up reports described a pattern where the measured frequency of progression to symptomatic heart failure was lower in the actively treated group. Results apply only to the populations studied, and evidence is limited regarding whether these observed patterns continue after treatment is stopped.

Evidence for Use in Managing Chronic Hypertension

Eril was evaluated in prospective clinical trials and large observational cohort studies for conditions characterized by chronic elevated pressure. Research examined outcomes primarily measuring the reduction in systolic and diastolic blood pressure (BP) over defined time intervals. Studies described a pattern of lower blood pressure measurements when the study drug was administered daily. Findings were mixed regarding blood pressure response based on factors like age and race in some research.

What Remains Unclear or Under Study

Evidence quality varies across studies, and limitations exist across the research landscape. Specifically, comparative evidence is lacking in some areas, such as the long-term, head-to-head comparison of Eril against all other available drug classes for kidney protection in diabetic patients. Also, long-term effects are not fully established regarding outcomes related to end-stage renal disease in the diabetic population.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Eril (FAQ)

Q: Does Eril interact with common herbal supplements?

Regulatory documents state that certain non-medicinal products can affect how Eril works in your body. This includes Grapefruit juice and some herbal products, such as St. John's Wort. These substances may alter the drug's exposure level, meaning the amount of Eril in your system could change.

Q: How does Eril lower blood pressure?

Eril is an ACE inhibitor, which means it works by blocking a process that forms a potent hormone called Angiotensin II. This hormone normally causes blood vessels to tighten, or constrict. By blocking it, Eril promotes the widening of blood vessels, which reduces the resistance against which the heart must pump blood and ultimately helps to lower high blood pressure.

Q: What are the signs of angioedema?

Angioedema is a serious, documented side effect that may occur while taking Eril. Official product information describes the signs as swelling of the face, lips, tongue, extremities, or the glottis and larynx (voice box/throat). Due to the potential for breathing issues, angioedema is regarded as a serious reaction requiring immediate attention.

Q: How long does it take for Eril to start working?

Official drug information on the action of Eril states that the blood pressure-lowering effect usually begins within one hour after taking a single oral dose. The maximum reduction in blood pressure for that dose is typically observed around four to six hours after administration.

Q: Is Eril available as a generic drug?

Yes. The active ingredient in Eril is Enalapril Maleate. This chemical name, Enalapril Maleate, is the generic name for the compound, which belongs to the Angiotensin-Converting Enzyme (ACE) Inhibitor class. Therefore, it is available in generic form.

Q: Can I drink alcohol while taking Eril?

Regulatory warnings indicate that consuming alcohol may increase the effects of Eril that lower blood pressure. This enhanced effect can lead to symptoms like dizziness or feeling lightheaded. This combination is noted in official sources.

Q: What should I do if I experience a persistent cough while taking Eril?

A persistent cough is listed in regulatory documents as a very common side effect of Eril. Since this can be bothersome or interfere with sleep, official patient information notes the need to consult your healthcare provider if the cough continues. Consulting your provider allows them to review your treatment plan.

Q: How is Eril eliminated from the body?

Pharmacokinetic data from official sources indicate that Eril is primarily converted to its active form, Enalaprilat, which is then eliminated from the body. This process occurs mainly through the kidneys and involves excretion into the urine.

How should Eril be stored and disposed of?

How to Store and Dispose of Eril: Official Regulatory Information

Official labeling mandates specific conditions to ensure Eril's stability and efficacy. The product must be stored at controlled room temperature, typically 20 C to 25 C. It is strictly required to protect the medicine from light and moisture, and the container must be kept tightly closed. Freezing or storing the product above 30 C is prohibited.

Handling and Disposal Requirements

Requirement	Official Statement
Child Safety	Keep Eril and all medications out of the sight and reach of children.
Disposal	Unused or expired medication must be managed through an authorized drug take-back program. If this is unavailable, mix the product with an undesirable substance and seal it before placing it in household trash.
Environmental	Do not dispose of the medicine by flushing it down the toilet or pouring it into a drain unless explicitly instructed to do so on the labeling.